Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia

Bartkó, György; Váradi, Hedvig; Simon, Lajos; Linka, Emese; Tüske, Tamás; Sántha, Judit

doi:10.1080/136515002753489362

Cited by 11 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar conclusions were reported by Rabinowitz and others, who studied patient satisfaction and burden of adverse effects with second-generation, compared with first-generation, antipsychotics (57). In a recent study of satisfaction and subjective experiences of patients with schizophrenia who switched from first-to second-generation antipsychotics, Bartko and others concluded that most patients experienced higher levels of satisfaction (58). This high level of satisfaction contributed to more favourable attitudes toward medication.…”

Section: Second-generation Antipsychotics Subjective Tolerability Asupporting

confidence: 73%

New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

Awad

Voruganti

2004

Can J Psychiatry

View full text Add to dashboard Cite

At present, the state of the art can only indicate a more favourable trend for second-generation antipsychotics in regard to improving medication adherence behaviour, quality of life, and subjective tolerability. It is surprising that such important outcomes, which are likely the defining factors in the superiority of second-generation antipsychotics, have not received adequate research attention. Well-designed, controlled, and adequately powered studies are urgently needed before any firm conclusions can be reached.

show abstract

Section: Second-generation Antipsychotics Subjective Tolerability Asupporting

confidence: 73%

New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

Awad

Voruganti

2004

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

“…Moreover, of those patients who had switched to quetiapine from a different antipsychotic, 97% preferred quetiapine to their previous medication, and the most common reasons for citing this preference were improved effectiveness and the absence or low frequency of adverse events. The findings of more recent studies are consistent with the Hellewell et al (1999) survey and confirm that quetiapine is acceptable to, and preferred by, patients 36,37 .…”

Section: Influence Of Tolerability On Treatment Selectionsupporting

confidence: 76%

Managing acute exacerbations of schizophrenia: focus on quetiapine

Arango¹,

Bobes²

2004

Current Medical Research and Opinion

View full text Add to dashboard Cite

In this commentary article we describe our clinical experience and provide our views on the use of quetiapine in the treatment of patients with acute exacerbations of schizophrenia. Some patients with acute schizophrenia may require parenteral medication; however, we believe that oral antipsychotics, either alone or in combination with other medications, have a key role to play as an initial and/or subsequent pharmacotherapeutic intervention. Quetiapine has beneficial calming properties and successfully treats the symptoms of aggression, anxiety and hostility that can accompany acute exacerbations of schizophrenia. Based upon a review of published findings, data presented at recent international psychiatric congresses and our clinical experience, we propose that a more rapid initiation schedule (for example, 400 mg by Day 2, increasing to 600 mg/day by Day 3 and often up to 800 mg/day by Day 4, or in severe cases 300 mg on Day 1, 600 mg on Day 2 and 900 mg on Day 3) than that currently described in quetiapine prescribing information can be used to provide safe, effective treatment in hospitalised patients with acute schizophrenia. (Note that lower doses are used in patients with first-episode schizophrenia.) Furthermore, while current prescribing information recommends that quetiapine be administered at doses up to 750 mg/day (800 mg/day in the USA and Canada), there is growing evidence that dosing up to 1600 mg/day of quetiapine has been well tolerated in some patients. In general, newer antipsychotics have superior tolerability profiles compared with conventional agents; however, clear differences in tolerability exist among the new generation antipsychotics. Quetiapine has an excellent tolerability profile offering high patient acceptability that, in turn, may promote patient adherence to medication and an improved quality of life. As such, we consider quetiapine to be a first-choice antipsychotic for the treatment of acute exacerbations of schizophrenia.

show abstract

“…A naturalistic study in patients who switched to atypical antipsychotics from conventional agents, demonstrated higher levels of satisfaction with atypical antipsychotic treatment than previous medication; the most frequent reason for preferring atypical antipsychotics was favourable tolerability [42]. Furthermore, in a study of patients' attitudes towards antipsychotic drugs, 51% of more than 300 non-adherent patients indicated that side effects were the main reason they stopped taking medication [43].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness, tolerability and subjective well-being in patients receiving quetiapine: findings of a post-marketing surveillance study in schizophrenia

Lambert¹,

Reimitz²

2006

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Objectives. Previous studies of antipsychotics have mainly focused on efficacy and tolerability. However, patient subjective well-being is increasingly being accepted as a valid and important measure of antipsychotic treatment outcomes and tolerability. Methods. In this open-label, observational trial data from 1322 outpatients with schizophrenia treated with flexibly dosed quetiapine were collected at baseline, Week 4 and Week 12. Patient well-being was assessed using Subjective Well-being under Neuroleptics (SWN-K) scale and disease severity with the Clinical Global Impressions-Severity of Illness (CGI-S) scale following quetiapine treatment. In addition, safety and tolerability were monitored throughout the study. Results. Quetiapine treatment, mean endpoint dose 337 mg/day, led to a significant reduction in disease severity, with improvements in CGI-S score of -0.7 at Week 4 and -1.3 at Week 12 (both P<0.001). In addition, patients' subjective well-being was significantly improved at Week 12, with a mean (SD) increase from baseline in SWN-K total score of 22.9 (18.7) (P<0.001). Further, an improved tolerability profile compared with previous medication was reported. Conclusions. This study emphasises the importance of patients' subjective well-being and the favourable acceptability of quetiapine among patients with schizophrenia.

show abstract

Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia

Cited by 11 publications

References 22 publications

New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

New Antipsychotics, Compliance, Quality of Life, and Subjective Tolerability—Are Patients Better Off?

Managing acute exacerbations of schizophrenia: focus on quetiapine

Effectiveness, tolerability and subjective well-being in patients receiving quetiapine: findings of a post-marketing surveillance study in schizophrenia

Contact Info

Product

Resources

About